Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Staged Treatment in Early Psychosis (STEP): A Sequential Multistage Randomized Clinical Trial (SMART) of Interventions for Ultra High Risk (UHR) of Psychosis Patients.

NCT02751632 is registered in ClinicalTrials.gov with Orygen as lead sponsor.

NCT NCT02751632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02751632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Staged Treatment in Early Psychosis (STEP): A Sequential Multistage Randomized Clinical Trial (SMART) of Interventions for Ultra High Risk (UHR) of Psychosis Patients.
Lead sponsor
Orygen
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2016
Completion date
May 31, 2022
Enrollment
342 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

clinical high risk, personality disorders, psychotic disorders